collected within 48 hours of admission. The samples were collected into plastic tubes containing ethylenediaminetetraacetic acid (EDTA-2Na, 1.5 mg/ml) and aprotinin (500 kallikrein inhibitor units/ml) and stored at 4C. After centrifugation, the collected plasma samples were stored at -80C until measurements were made.
Measurement of two BNP forms. Plasma total BNP and proBNP were measured using the chemiluminescence enzyme immunoassays (CLEIAs) as previously described 8, 15 . Briefly, in both
CLEIAs, an antibody recognizing a common epitope in the C-terminal region of proBNP and mature BNP was used as a capture antibody. An antibody recognizing the N-terminal region of proBNP and one recognizing the ring region of BNP were used as detection antibodies in the proBNP and total BNP CLEIAs, respectively. Glycosylated proBNP with a relative molecular mass of 32 kDa (HyTest, Turku, Finland) served as the standard. Intra-assay (8 replicates) and inter-assay (10 replicates) coefficients of variation of the standard peptide at 2.6, 8.9, and 76.7 pmol/l (pM) were in the ranges of 1.5-5.4%
and 4.1-5.5%, respectively, in the proBNP assay.
Cyclic guanosine monophosphate (cGMP) and other laboratory markers. The second messenger mediating the effects of ANP and BNP, cGMP, was measured using a radioimmunoassay assay kit (Yamasa Co, Tokyo, Japan). Estimated glomerular filtration rate (eGFR) was calculated using the equation 
